Corteselli, Elizabeth M.
Sharafi, Mona
Hondal, Robert
MacPherson, Maximilian
White, Sheryl
Lam, Ying-Wai
Gold, Clarissa
Manuel, Allison M.
van der Vliet, Albert http://orcid.org/0000-0003-0923-0016
Schneebeli, Severin T. http://orcid.org/0000-0002-9511-9922
Anathy, Vikas
Li, Jianing http://orcid.org/0000-0002-0143-8894
Janssen-Heininger, Yvonne M. W. http://orcid.org/0000-0002-2735-8745
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R35HL135828)
Article History
Received: 28 June 2021
Accepted: 21 June 2023
First Online: 28 July 2023
Competing interests
: Yvonne Janssen-Heininger and Vikas Anathy hold patents: United States Patent No. 8,679,811, “Treatments Involving Glutaredoxins and Similar Agents” (YJ-H, VA), United States Patent No. 8,877,447, “Detection of Glutathionylated Proteins” (YJ-H), United States Patents 9,907,828 and 10,688,150 “Treatments of oxidative stress conditions” (YJ-H, VA). Yvonne Janssen-Heininger and Vikas Anathy have received consulting fees from Celdara Medical LLC for their contributions to the proposed commercialization of glutaredoxin for the treatment of pulmonary fibrosis. The remaining authors declare no competing interests.